Cargando…

Cost-effectiveness analysis of vaccination against COVID-19 in China

INTRODUCTION: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huixuan, Ding, Ningxin, Han, Xueyan, Zhang, Hanyue, Liu, Zeting, Jia, Xiao, Yu, Jingjing, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027744/
https://www.ncbi.nlm.nih.gov/pubmed/36960359
http://dx.doi.org/10.3389/fpubh.2023.1037556
_version_ 1784909774807105536
author Zhou, Huixuan
Ding, Ningxin
Han, Xueyan
Zhang, Hanyue
Liu, Zeting
Jia, Xiao
Yu, Jingjing
Zhang, Wei
author_facet Zhou, Huixuan
Ding, Ningxin
Han, Xueyan
Zhang, Hanyue
Liu, Zeting
Jia, Xiao
Yu, Jingjing
Zhang, Wei
author_sort Zhou, Huixuan
collection PubMed
description INTRODUCTION: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. METHODS: In this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. RESULTS: Our simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. CONCLUSION: Compared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses.
format Online
Article
Text
id pubmed-10027744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100277442023-03-22 Cost-effectiveness analysis of vaccination against COVID-19 in China Zhou, Huixuan Ding, Ningxin Han, Xueyan Zhang, Hanyue Liu, Zeting Jia, Xiao Yu, Jingjing Zhang, Wei Front Public Health Public Health INTRODUCTION: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. METHODS: In this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. RESULTS: Our simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. CONCLUSION: Compared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027744/ /pubmed/36960359 http://dx.doi.org/10.3389/fpubh.2023.1037556 Text en Copyright © 2023 Zhou, Ding, Han, Zhang, Liu, Jia, Yu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Zhou, Huixuan
Ding, Ningxin
Han, Xueyan
Zhang, Hanyue
Liu, Zeting
Jia, Xiao
Yu, Jingjing
Zhang, Wei
Cost-effectiveness analysis of vaccination against COVID-19 in China
title Cost-effectiveness analysis of vaccination against COVID-19 in China
title_full Cost-effectiveness analysis of vaccination against COVID-19 in China
title_fullStr Cost-effectiveness analysis of vaccination against COVID-19 in China
title_full_unstemmed Cost-effectiveness analysis of vaccination against COVID-19 in China
title_short Cost-effectiveness analysis of vaccination against COVID-19 in China
title_sort cost-effectiveness analysis of vaccination against covid-19 in china
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027744/
https://www.ncbi.nlm.nih.gov/pubmed/36960359
http://dx.doi.org/10.3389/fpubh.2023.1037556
work_keys_str_mv AT zhouhuixuan costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT dingningxin costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT hanxueyan costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT zhanghanyue costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT liuzeting costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT jiaxiao costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT yujingjing costeffectivenessanalysisofvaccinationagainstcovid19inchina
AT zhangwei costeffectivenessanalysisofvaccinationagainstcovid19inchina